

**Merrion Pharmaceuticals to present at UBS 2010 Global Specialty
Pharmaceuticals Conference in London**

DUBLIN, IRELAND, 01 June 2010 - Merrion Pharmaceuticals plc (MERR:ESM) today announced its participation, in the prestigious UBS Global Specialty Pharmaceuticals Conference in London. The company will be presenting at 10.30am GMT, Wednesday 2nd June 2010 (UBS Offices, 1 Finsbury Ave, London).

The 14th annual UBS Global Specialty Pharmaceuticals Conference provides a unique opportunity to access European and Global investors, as well as to meet other leading specialty pharmaceutical companies from around the world. The conference features presentations from top executives at leading international generic and specialty pharmaceutical companies from around the world. It also provides opportunities for one on one meetings with investors and company to company meetings for commercial and strategic opportunities.

Media Enquiries:

Merrion Pharmaceuticals plc
Jonathan O'Connell
+353 1 6423300
www.merrionpharma.com

Brunswick Group
Jon Coles
Will Carnwath
T +44 207 404 5959
Merrion@brunswickgroup.com

Griffin Integrated Communications
Daniel O'Connell
T 212.481.3456, ext 16
F 212.684.0606
Doconnell@griffinpr.com

About Merrion:

Merrion Pharmaceuticals (www.merrionpharma.com) is a publicly listed product development company focused on delivering innovation to the market by working on our own products and partnering to develop strategic products. Established in 2003 to commercialise various technologies acquired from Elan Corporation, Merrion are engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion Pharmaceutical's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. This can provide substantial benefits in patient convenience and safety, and might also provide enhanced drug efficacy. Merrion utilises its technology to develop new oral drugs in two ways; it develops its own proprietary drugs using GIPET and partners with other pharmaceutical companies in developing oral GIPET formulations of their products.

Merrion has agreements with several pharmaceutical companies. Merrion has two license agreements with Novo Nordisk A/S to develop and commercialise oral forms of Novo Nordisk's Insulin and GLP-1 using Merrion's proprietary GIPET technology. Merrion also has an oral drug delivery research collaborative program with Ferring Pharmaceuticals, a Swiss based international pharmaceutical company.

Merrion Pharmaceuticals is based in Dublin, in a state of the art purpose built facility which allows speed of development and reduced risk in taking ideas from conception to final phase II formulation in our own cGMP facilities. Merrion also has operations in Wilmington, North Carolina.

Merrion is listed on the Irish Stock Exchange (ESM) under the symbol MERR.

About UBS Conference:

14th annual UBS Global Specialty Pharmaceuticals Conference will be held Wednesday, 2 - Thursday, 3 June 2010 at the UBS offices in London.

For further information visit:

<http://www.ibb.ubs.com/conferences/emea/globalpharmaconfldn2010/index.html>

UBS Offices
1 Finsbury Avenue
London EC2M 2PP